Possible / Probable News Flow (supplement to #msg-20149243):
1. A partnership for ATryn in Japan. Japan has substantial sales of plasma-derived antithrombin, including an approved indication for DIC/sepsis. These plasma-derived sales represent low-hanging fruit for eventual conversion to ATryn. At least one Japanese clinical study (by a GTC partner) will be needed to obtain marketing approval.
2. A development partner for GTC’s CD137 program. This would be especially significant in that it would signify that GTC can once again be a player in monoclonal antibodies.
3. More deals similar to the ones with Merrimack and PharmAthene. The effect of such announcements on the stock price could be large, depending of course on the partner and the drug.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.